Renew Biotechnologies today announced the publication of its peer-reviewed research in Frontiers in Neurology, providing evidence that native DNA methylation analysis can identify neuron-associated cell-free DNA (cfDNA) signatures in blood across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).